Industry-Academy Collaboration for Pioneering New Medicine Mudi Sheves Vice President for Technology Transfer Weizmann Institute of Science; Israel KoNECT International conference 2016 Nov. 1st 2016 Conference 2016

Basic Research Landscape Weizmann Approach: Basic Research Landscape Physics Basic Science only Imbedded multidisciplinary approach Graduate school and Public Education Mathematics Biology Chemistry High level education program Intellectual Property rules and technology transfer

Technological developments are fueled by scientific innovations coming from academia. “The guy who invented the first wheel was an idiot. The guy who invented the other three, he was a genius”. Sid Caesar

“Society, having funded much of the university based research, has an  too little “Society, having funded much of the university based research, has an expectation that the fruits of that research will improve the human condition.” Niels Reimers, 1987

Academy- Pharma Industry Interactions The death valley

Basic research Translational research

Yeda / Weizmann Success Stories Selected Success Stories  COPAXONE® Indicated for Multiple Sclerosis COPAXONE represents a new class of drugs for the treatment of the disease Copaxone is a synthetic copolymer acting as an immunomodulator 1971: First Patent filed by Yeda 1987: Licensed to Teva Pharmaceuticals Ltd. 2015 Sales: $US 4 Billion Share market: ca. 32% Ci C Coincident (serendipity) is the way of god to stay anonymous A. Einstein

Selected Success Stories Yeda / Weizmann Success Stories  Rebif® Indicated for Multiple Sclerosis Rebif is a recombinant interferon beta 1a. Rebif is marketed worldwide by Merck Serono. 1982: Licensed to Interpharm. 2015 Sales: Euro 2.5 Billion

Selected Success Stories Yeda / Weizmann Success Stories  ErbituxTM Erbitux is an antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented by Prof. Sela’s group at WIS between 1987-88. Erbitux was developed by ImClone Systems and approved by the FDA in 2001. Estimated yearly sales - $2.5 billion.

FROM A SINGLE PATENT TO THREE DRUGS MARCH2016 $2,500 MILLION Prof. Sela and colleagues discovered that EGFR-inhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy The three EGFR blockers are saving the lives of hundreds of thousands of cancer patients all over the world $2,500 MILLION Erbitux® Merck and Eli Lilly metastatic colorectal cancer EGFR BLOCKERS $549 MILLION Vectibix® AMGEN Colorectal cancer $500 M (EST 2016) Portrazza® Eli Lilly Lung cancer

18.03.1992 Building the Future of Cancer Therapy (ImmunoTherapy?) PATENT FILED BY PROF. ZELIG ESHHAR Prof. Zelig Eshhar, The Israel Prize 2015 And Massry Prize 2014 Winner

Breakthrough Leukemia Therapy source: KITE PHARAMA CORPORATE PRESENTATION February 2016 Prof. Eshhar began working on the concept for the therapy in the 1980s. “We knew that the T-cells have the ability to destroy tissue. The question was how to convince them to attack cancerous tissue, which they do not normally recognize as foreign or harmful” 94% SUCCESS RATE IN TRIAL BASED ON RESEARCH OF PROF. ZELIG ESHHAR

May 2014

TOOKAD- Prof. A. Scherz and Prof. Y. salomon Patent- 1993; Agreement 1996

Magnetic resonance images of the prostate gland after treatment with TOOKAD Soluble. The black regions show the portions of the prostate that have been eliminated to remove the previously detected cancerous tissue

Yeda Research & Development Co. Ltd. A World Leader in Technology Transfer Dozens of “Weizmann-Inside” products on the market. Total annual Weizmann based technologies products sales in 2015: Over $35 Billion. Over 50 new companies were established around Yeda’s technologies. Yeda owns one of the largest portfolio of patents in Israel: 660 live patent families, with more than 1,700 patent families filed since 1971.

Annual sales of products based on technologies developed at the Weizmann Institute of Science

Cooperation with industrial partners Add Amgen

“The true sign of intelligence is not knowledge but imagination” “The true sign of intelligence is not knowledge but imagination”. “Insanity: doing the same thing over and over again and expecting different results”. Albert Einstein

Thanks for Your Attention

Develop next generation T cell therapy Enhance T cell function by modulating immune synapse using the vIgD technology Overcome immune suppression through combination therapy and gene modulation source: KITE PHARAMA CORPORATE PRESENTATION February 2016

“Miracles sometimes occur, but one has to work terribly hard for them” Prof. Haim Weizmann